Literature DB >> 9869611

Limited humoral immunity in hepatitis C virus infection.

M Chen1, M Sällberg, A Sönnerborg, O Weiland, L Mattsson, L Jin, A Birkett, D Peterson, D R Milich.   

Abstract

BACKGROUND & AIMS: The extremely high rate of chronicity to hepatitis C virus (HVC) infection suggests an inefficient immune response. The humoral immune response to HCV was evaluated in 60 patients with chronic HCV infection and in 12 patients acutely infected with HCV.
METHODS: A number of recombinant HCV antigens including the core, envelope 2 (E2), nonstructural (NS) 3, NS4, and NS5 proteins, and NS4a and E2-HVR-1 peptides were used in enzyme-linked immunoassays.
RESULTS: Immunoglobulin (Ig) G antibody responses to these viral antigens, except for the HCV core, were highly restricted to the IgG1 isotype. The prevalence of antibodies of the IgG1 isotype specific for the HCV core, E2, E2-HVR1, NS3 (helicase domain), NS4, and NS5 antigens was 97%, 98%, 28%, 88%, 33%, and 68%, respectively. Antibodies of the IgG3 isotype specific for E2, E2-HVR-1, NS3, NS4, and NS5 were detected in a minority of serum samples. The IgG2 and IgG4 isotypes were rarely if ever detected. Furthermore, antibody responses to HCV viral antigens were of relatively low titer and, with the exception of anti-HCV core, were delayed in appearance until the chronic phase of infection.
CONCLUSIONS: The IgG1 restriction, low titer, and delayed appearance of antibody responses elicited during HCV infection suggest that the immunogenicity of HCV proteins is limited in the context of natural infection. Inasmuch as recombinant HCV viral antigens perform as relatively normal immunogens in small animals, we suggest that the defective humoral immune responses during HCV infection may be attributable to an "immune avoidance" strategy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9869611     DOI: 10.1016/s0016-5085(99)70237-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  53 in total

Review 1.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

2.  Early IL-10 predominant responses are associated with progression to chronic hepatitis C virus infection in injecting drug users.

Authors:  J K Flynn; G J Dore; M Hellard; B Yeung; W D Rawlinson; P A White; J M Kaldor; A R Lloyd; R A Ffrench
Journal:  J Viral Hepat       Date:  2010-07-05       Impact factor: 3.728

3.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Evidence for prostaglandin-producing supressor cells in HCV patients with normal ALT.

Authors:  Rui Marinho; Ruth Pinto; Maria Livia Santos; MouraMiguelCarneiro de
Journal:  Dig Dis Sci       Date:  2002-03       Impact factor: 3.199

5.  Transcriptional repression of C4 complement by hepatitis C virus proteins.

Authors:  Arup Banerjee; Budhaditya Mazumdar; Keith Meyer; Adrian M Di Bisceglie; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2011-02-23       Impact factor: 5.103

6.  Genetic markers of IgG influence the outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Yuqun Luo; Yuping Wu; Robert C Elston; David L Thomas; Hugo R Rosen; James J Goedert
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

Review 7.  Progress in the development of vaccines for hepatitis C virus infection.

Authors:  Faezeh Ghasemi; Sina Rostami; Zahra Meshkat
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

8.  Induction of IgA and sustained deficiency of cell proliferative response in chronic hepatitis C.

Authors:  Yalena Amador-Cañizares; Liz Alvarez-Lajonchere; Ivis Guerra; Ingrid Rodríguez-Alonso; Gillian Martínez-Donato; Julián Triana; Eddy E González-Horta; Angel Pérez; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

9.  Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes.

Authors:  G Ahlén; E Derk; M Weiland; J Jiao; N Rahbin; S Aleman; D L Peterson; K Pokrovskaja; D Grandér; L Frelin; M Sällberg
Journal:  Gut       Date:  2008-08-08       Impact factor: 23.059

10.  Hepatitis C virus core, NS3, NS4B and NS5A are the major immunogenic proteins in humoral immunity in chronic HCV infection.

Authors:  Maarit Sillanpää; Krister Melén; Päivi Porkka; Riku Fagerlund; Kaisu Nevalainen; Maija Lappalainen; Ilkka Julkunen
Journal:  Virol J       Date:  2009-06-23       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.